General Practice Research Database Seroquel XR Safety Study (GPRD SeroquelS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.
The outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs [ Time Frame: During follow-up of a treatment episode estimated to be on average of 1.5 years ]
Duration of treatment [ Time Frame: During follow-up estimated to be on average of 1.5 years. ]
Duration of treatment episode [ Time Frame: During follow-up estimated to be on average of 1.5 years ]
Episode, defined as the treatment time from first to last prescription of quetiapine XR or other study drugs.
Comorbidities defined by clinical diagnosis or prescription [ Time Frame: Baseline and during follow up of treatment estimated to be on average 1.5 years ]
Age [ Time Frame: Baseline ]
Gender [ Time Frame: Baseline ]
Dose [ Time Frame: During follow-up of treatment estimated to be on average 1.5 years ]
Adherence [ Time Frame: During follow-up of treatment estimated to be on average 1.5 years ]
The number of subjects to whom the drug was prescribed by the general practitioners. [ Time Frame: During follow-up of treatment estimated to be on average 1.5 years ]
The number of patients, whom the drug was prescribed by the specified type of prescriber (specialist, general practitioner or another type of physician).
Indication for treatment [ Time Frame: During follow-up of treatment estimated to be on averaged 1.5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A sample of the general population in the UK consisting of 3 millions inhabitants.
Episodes of new use (>/=1 prescription) of quetiapine XR or other study drugs
Less than two years of recorded history before the start of the marketing of quetiapine XR (or cohort entry date)
If the duration and dose of the antipsychotic drug cannot be determined
Depressive Disorder, Major
Schizophrenia Spectrum and Other Psychotic Disorders
Bipolar and Related Disorders
Central Nervous System Depressants
Physiological Effects of Drugs